Endocrine Abstracts

Diabetes mellitus (DM) is a global medical and social problem of our time, which is faced by medical science and healthcare in almost all countries of the world. The situation in Uzbekistan follows the global trend. According to 2019 data, 230 610 patients with diabetes are registered in the country: 18 349 patients with type 1 diabetes and 212 261 - with type 2 diabetes. According to screening studies, the prevalence of type 2 diabetes in Uzbekistan over the past 14 years has increased 1.6 times and, according to the latest data (2015).

Aim: To study the functional state of the kidneys and lipid metabolism while using iSGLT-2 in patients with type 2 diabetes mellitus with diabetic nephropathy.

Materials and Methods: We studied 40 patients with T2DM with DN (CKD C2, A2). The average age was 52.7 ± 3.78 years; diabetes experience - 8 years; BMI-30 ± 0.17; Hb1C-9.2 ± 0.4%; fasting glycemia –10.2 mmol/; eGFR-78 ml/min; TG-2.7 ± 0.44; total cholesterol-3.4 ± 0.72; MAU 32 ± 0.125.

Results: 6 months after the start of ingestion of iSGLT-2, the patients showed an improvement in renal function and lipid metabolism. According to laboratory data, there is a significant (P < 0.001) decrease in creatinine levels by 7.4 μmol/l (93.8 ± 0.05) and an increase in eGFR by 5.3 ml/min /1.73 m². Despite the fact that the doses of statins did not change, we observed a significant (P < 0,05) decrease in total cholesterol levels by 1.04 mmol/l and triglycerides by 1.17 mmol/l.

Conclusion: In our study, we observed a significant decrease in the level of atherogenic fractions of the lipid spectrum. Also, the dynamics of creatinine and eGFR levels confirms the safety of the drug and some nephroprotective effect, which manifests itself with a sufficiently short observation period.